Project Grant R21CA307422
Award Date 7/3/26
Completion Date 6/30/28
Dollars Obligated $454K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded University of Massachusetts Medical School a $530,050 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective July 1, 2026, with completion targeted for June 30, 2031. This award supports the development of a multi-targeted nanoparticle-based immunotherapy platform designed to overcome immune suppressive barriers in pancreatic ductal adenocarcinoma (PDAC). The research focuses on engineering lipid...
- Federal Grant Award Summary Brigham and Women's Hospital, Inc. received a $772,208 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective April 10, 2026, through March 31, 2031. The grant funds research on macrophage-directed strategies to enhance PARP (poly(ADP-ribose) polymerase) inhibitor efficacy in BRCA-associated breast cancer. The project delivers two primary research products: (1) translational biomarker analysis...
- Federal Project Grant Award Summary The University of Massachusetts received a $832,936 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective June 26, 2026, through May 31, 2031. The grant supports development of a novel dual-adjuvant, dual-delivery nanoparticle (NP) cancer vaccine platform designed to overcome critical barriers in cancer immunotherapy. The research centers on a "prime-pull" vaccination...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $1.71 million Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective September 1, 2025, through July 31, 2032. The award funds research into new approaches to targeting cell cycle proteins, specifically cyclin-dependent kinases (CDKs), for cancer treatment. The research addresses three critical therapeutic gaps: developing strategies to induce tumor cell...
- Federal Grant Award Summary The Broad Institute of MIT and Harvard received a $443,564 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded on September 2, 2025, with completion by August 31, 2027. The award supports the development of a novel cancer immunotherapy platform utilizing engineered commensal skin bacteria to stimulate tumor-specific T cell immunity. The research focuses on leveraging Staphylococcus epidermidis, a naturally...
- Federal Grant Award Summary Dana-Farcer Cancer Institute, Inc. received a $718,275 Project Grant from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) effective July 1, 2026, through June 30, 2031. The award supports fundamental research investigating context-specific pathway dependencies for nuclear envelope (NE) proteins in brain cancer. The project employs large-scale human cancer cell fitness screens and an analytical framework called WEBSTER to...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Massachusetts General Hospital a $707,798 Project Grant under the Cancer Biology Research program (CFDA 93.396) beginning April 1, 2026, and concluding March 31, 2031. The award funds research to determine mechanisms of heterogeneous treatment response in glioblastoma (GBM), an aggressive brain tumor that typically recurs in treatment-resistant form within months of standard-of-care treatment. The primary deliverable is...
- Federal Grant Award Summary The National Cancer Institute awarded Columbia University a Project Grant of $702,132 under the Cancer Treatment Research program (CFDA 93.395) to conduct multiplex single-cell chemical genomics research focused on identifying small molecule modulators of glioblastoma immunogenicity. The project, which commenced June 11, 2026 and concludes May 31, 2029, will deliver high-throughput chemical transcriptomic profiling screening against 3,792 small molecules to...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Nanocan Therapeutics Corporation a $2.996 million Project Grant under the Cancer Treatment Research program (CFDA 93.395) on September 24, 2025, to conduct the first clinical trial demonstrating the safety of the Liquid Immunotherapeutic Fiducial Eluter (LIFE) Gel product and treatment protocol. This Phase II Small Business Technology Transfer (STTR) project, conducted in collaboration with Johns Hopkins University and...